1. S. Best, P. Gubser, S. Sethumadhavan, A. Kersbergen, Y. Negrón Abril, J. Goldford, K. Sellers, W. Abeysekera, A. Garnham, J. McDonald, C. Weeden, D. Anderson, D. Pirman, T. Roddy, D. Creek, A. Kallies, G. Kingsbury, K. Sutherland. Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer. Cell Metab. 2022. *Co-corresponding author. PMID: 35504291
2. J. Hess, K. Sutherland and S. Best. Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. Transl Lung Cancer Res. 2021. 10(6) 2788-2805. *Senior and co-corresponding author. PMID: 34295678
3. S. Best, C. Vandenberg, E. Abad, L. Whitehead, L. Guiu, S. Ding, M. Brennan, A. Strasser, M. Herold, K. Sutherland, A. Janic. Consequences of Zmat3 loss in C-MYC and mutant KRAS-driven tumorigenesis. Cell Death Dis. 2020. 11(10):877. PMID: 33082333
4. S. Best*, J. Hess*, F. Souza-Fonseca-Guimaraes, J. Cursons, A. Kersbergen, X. Dong, J. Rautela, S. Hyslop, M. Ritchie, M. Davis, T. Leong, L. Irving, D. Steinfort, N. Huntington, K. Sutherland. Harnessing natural killer immunity in metastatic small cell lung cancer. J Thorac Oncol. 2020. 15(9):1507-1521. *Equal contribution. PMID: 32470639
5. S. Best, S. Ding, A. Kersbergen, X. Dong, J.Y. Song, Y. Xie, B. Reljic, K. Li, J. Vince, V. Rathi, G. Wright, M. Ritchie, K. Sutherland. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nat Commun. 2019. 10(1):4190. PMID: 31519898
6. S. Best*, C. Harapas*, A. Kersbergen, V. Rathi, M.L. Asselin-Labat, K. Sutherland. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. Oncogene. 2018. 37(46):6096-6104. *Equal contribution. PMID: 29991799
7. S. Best and K. Sutherland. “KEAPing” a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle. 2018. 17(14):1696-1707. PMID: 30009666
8. S. Best, D. DeSouza, A. Kersbergen, A. Policheni, S. Dayalan, D. Tull, V. Rathi, D. Gray, M. Ritchie, M. McConville, K. Sutherland. Synergy between the KEAP1/NRF2 and PI3K pathway drives non-small cell lung cancer with an altered immune microenvironment. Cell Metab. 2018. 27(4):935-943.e4. PMID: 29526543
9. S. Best, A. Kersbergen, M.L Asselin-Labat, K. Sutherland. Combining cell type-restricted adenoviral targeting with immunostaining and flow cytometry to identify cells-of-origin of lung cancer. Methods Mol Biol. 2018. 1725:15-29. PMID: 29322405
10. S. Best, A. Nwaobasi, C. Schmults, M. Ramsey. CCAR2 is required for proliferation and tumour maintenance in human Squamous Cell Carcinoma. J Invest Dermatol. 2017. 137(2):506-512. PMID: 27725203